A new analysis by the Clinical Trials Transformation Initiative (CTTI) shows just 14 percent of U.S. COVID-19 studies launched during the pandemic were completed. While the remaining 86 percent of trials remain active, many have either not reported results or will never be completed. Read More
A new study finds that trials sponsored by the pharma industry fared better during the pandemic and were more likely to complete enrollment compared to trials sponsored by academia, hospitals and medical centers. Read More
The World Health Organization (WHO) is considering launching a global platform trial by July to test three to four COVID-19 vaccines against placebo in partnership with several unnamed vaccine developers. Read More
Despite the unprecedented disruption and shift in priorities that COVID-19 brought to FDA’s Office of New Drugs (OND) in 2020, the office’s annual report shows it reviewed more than 320 trials for potential COVID-19 therapeutics and more than 570 drug development programs in the planning stages. Read More
Master protocols, having shown their usefulness in COVID-19 and oncology research, are on the rise and expected to expand into other therapeutic areas. But even with the strong backing of regulators, challenges remain for master protocol studies to become more commonplace. Read More
RSS
